Strain Name:

B6;129-Tgfbr2tm1Karl/J

Stock Number:

012603

Order this mouse

Availability:

Repository- Live

These floxed mutant mice possess loxP sites flanking exon 4 of the transforming growth factor, beta receptor II (Tgfbr2) (commonly referred to as TβRII) targeted gene. This strain may be useful for studying the cellular and mechanical role of TGF-β in regulating development, hematopoiesis, wound healing, and immune function.

Description

Strain Information

Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemHomozygote x Homozygote         (Female x Male)   25-NOV-13
Specieslaboratory mouse
GenerationF?+F5 (11-DEC-13)
Generation Definitions
 
Donating Investigator Stefan Karlsson,   Lund University Hospital

Description
These TβRII floxed mutant mice possess loxP sites flanking exon 4 of the targeted gene. Mice that are homozygous for this allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. When these mutant mice are bred to mice that express Cre recombinase, resulting offspring will have exon 4 deleted in cre-expressing tissues. This strain may be useful for studying the cellular and mechanical role of TGF-β in regulating development, hematopoiesis, wound healing, and immune function.

For example, when crossed to a strain expressing Cre recombinase in the neural tube, midbrain and dorsal spinal cord (see Stock No. 007807), this mutant mouse strain may be useful in studies of DiGeorge syndrome.

For example, when crossed to a strain expressing interferon inducible Cre recombinase (see Stock No. 003556), this mutant mouse strain may be useful in studies of autoimmune inflammation.

Development
A targeting vector was designed to insert a loxP-flanked neomycin resistance (neo) cassette upstream of exon 4, and a single loxP site downstream of exon 4 of the transforming growth factor beta (TGF-β) type II receptor (Tgfbr2) gene. The construct was electroporated into (129X1/SvJ x 129S1/Sv)F1-Kitl+-derived R1 embryonic stem (ES) cells. Correctly targeted ES cells were transiently transfected with a pIC-Cre expression plasmid to delete the neo cassette. Resulting ES cells contained multiple gene rearrangments; intact floxed-exon 4, intact floxed-neo cassette, or excision of both exon 4 and the neo cassette. Correctly targeted ES cells, containing only the floxed-exon 4, were injected into C57BL/6 blastocysts and resulting chimeric males were bred with C57BL/6 females. Resulting offspring were bred to establish a colony of TβRII mice. Upon arrival, mice were bred to C57BL/6J inbred mice (Stock No. 000664) for at least one generation to establish the colony.

Control Information

  Control
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls

Related Strains

Facebase: models
007664   129S-Efnb1tm1Sor/J
000646   A/J
000647   A/WySnJ
005709   B6.129-Skitm1Cco/J
002619   B6.129-Tgfb3tm1Doe/J
007453   B6.129P2(Cg)-Dhcr7tm1Gst/J
010525   B6.129S-Notch2tm3Grid/J
010616   B6.129S1-Jag1tm1Grid/J
010546   B6.129S1-Jag2tm1Grid/J
010620   B6.129S1-Notch2tm1Grid/J
009387   B6.129S1-Osr1tm1Jian/J
009386   B6.129S1-Osr2tm1Jian/J
010621   B6.129S1-Snai1tm2.1Grid/J
010617   B6.129S1-Snai2tm1Grid/J
003865   B6.129S2-Itgavtm1Hyn/J
003755   B6.129S4-Meox2tm1(cre)Sor/J
016902   B6.129S5-Irf6Gt(OST398253)Lex/J
003336   B6.129S7-Cdkn1ctm1Sje/J
012843   B6.129X1(Cg)-Slc32a1tm1.1Bgc/J
000026   B6.C3-Gli3Xt-J/J
004275   B6.Cg-Fignfi/Frk
012844   B6.Cg-Gad1tm1.1Bgc/J
006382   B6;129-Casktm1Sud/J
002711   B6;129-Gabrb3tm1Geh/J
004293   B6;129-Shhtm2Amc/J
010618   B6;129S-Jag1tm2Grid/J
010686   B6;129S-Snai1tm2Grid/J
009389   B6;129S1-Bambitm1Jian/J
010619   B6;129S1-Lfngtm1Grid/J
010547   B6;129S1-Notch3tm1Grid/J
010544   B6;129S1-Notch4tm1Grid/J
010722   B6;129S1-Snai2tm2Grid/J
012463   B6;129S4-Foxd1tm1(GFP/cre)Amc/J
022358   B6;129S6-Rr23tm1Axvi/Mmjax
022359   B6;129S6-Rr24tm1Axvi/Mmjax
022360   B6;129S6-Rr25tm1Axvi/Mmjax
003277   B6;129S7-Acvr2atm1Zuk/J
002788   B6;129S7-Fsttm1Zuk/J
002990   B6;129S7-Inhbatm1Zuk/J
000523   B6By.Cg-Eh/J
000278   B6C3Fe a/a-Papss2bm Hps1ep Hps6ru/J
000515   B6CBACa Aw-J/A-SfnEr/J
001434   C3HeB/FeJ x STX/Le-Mc1rE-so Gli3Xt-J Zeb1Tw/J
000252   DC/LeJ
005057   FVB.129-Kcnj2tm1Swz/J
012655   FVB.A-Irf6clft1/BeiJ
013100   FVB.C-Prdm16csp1/J
017437   FVB/N-Ckap5TgTn(sb-cHS4,Tyr)2320F-1Ove/J
017438   FVB/N-MidnTg(Tyr)2261EOve/J
017609   FVB/N-Rr16Tn(sb-Tyr)1HCeb/OveJ
017598   FVB/N-Sdccag8Tn(sb-Tyr)2161B.CA1C2Ove/J
017608   FVB/N-Skor2Tn(sb-Tyr)1799B.CA7BOve/J
017436   FVB/N-Tapt1TgTn(sb-cHS4,Tyr)2508GOve/J
016870   FVB/NJ-Ap2b1Tg(Tyr)427Ove/EtevJ
017434   FVB;B6-Cramp1lTgTn(sb-rtTA,Tyr)2447AOve/J
017594   FVB;B6-Eya4TgTn(Prm1-sb10,sb-Tyr)1739AOve/J
017435   FVB;B6-SlmapTn(sb-rtTA)2426B.SB4Ove/J
003318   STOCK Shhtm1Amc/J
003102   STOCK Tgfb2tm1Doe/J
018624   STOCK Tgfb3tm2(Tgfb1)Vk/J
008469   STOCK Wnt9btm1.2Amc/J
View Facebase: models     (61 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).
DiGeorge Syndrome; DGS
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Colorectal Cancer, Hereditary Nonpolyposis, Type 6; HNPCC6   (TGFBR2)
Esophageal Cancer   (TGFBR2)
Loeys-Dietz Syndrome 2; LDS2   (TGFBR2)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Tgfbr2tm1Karl/Tgfbr2tm1Karl

        involves: 129S1/Sv * 129X1/SvJ * C57BL/6
  • normal phenotype
  • no abnormal phenotype detected   (MGI Ref ID J:77844)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tgfbr2tm1Karl/Tgfbr2tm1Karl Tg(Mx1-cre)1Cgn/0

        involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA   (conditional)
  • mortality/aging
  • premature death
    • after induction with polyI:polyC, death 8 - 10 weeks after   (MGI Ref ID J:77844)
  • behavior/neurological phenotype
  • abnormal stationary movement
    • after induction with polyI:polyC, unsteady   (MGI Ref ID J:77844)
  • paralysis
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • digestive/alimentary phenotype
  • stomach inflammation
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • endocrine/exocrine gland phenotype
  • pancreas inflammation
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • small thymus
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • growth/size/body phenotype
  • weight loss
    • after induction with polyI:polyC, dramatic   (MGI Ref ID J:77844)
  • immune system phenotype
  • increased inflammatory response
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
    • eye inflammation
      • after induction with polyI:polyC   (MGI Ref ID J:77844)
    • liver inflammation
      • after induction with polyI:polyC   (MGI Ref ID J:77844)
    • pancreas inflammation
      • after induction with polyI:polyC   (MGI Ref ID J:77844)
    • stomach inflammation
      • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • small thymus
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • liver/biliary system phenotype
  • liver inflammation
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • vision/eye phenotype
  • eye inflammation
    • after induction with polyI:polyC   (MGI Ref ID J:77844)
  • hematopoietic system phenotype
  • small thymus
    • after induction with polyI:polyC   (MGI Ref ID J:77844)

Tgfbr2tm1Karl/Tgfbr2tm1Karl Tg(Wnt1-cre)11Rth/0

        involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA   (conditional)
  • mortality/aging
  • perinatal lethality   (MGI Ref ID J:96359)
  • craniofacial phenotype
  • abnormal craniofacial bone morphology
    • malformations of cranial bones at E18   (MGI Ref ID J:96359)
  • cleft secondary palate   (MGI Ref ID J:96359)
    • palatal shelves fail to meet at midline   (MGI Ref ID J:96359)
  • cardiovascular system phenotype
  • abnormal aortic arch and aortic arch branch attachment
    • abnormal branching of the left carotid artery from the brachiocephalic trunk in mutant mice   (MGI Ref ID J:96359)
  • abnormal blood vessel physiology   (MGI Ref ID J:96359)
    • abnormal vasodilation
      • exhibit vasodilatation of the jugular veins   (MGI Ref ID J:96359)
  • congestive heart failure
    • heart defects lead to functional right-sided heart failure with venous congestion, resulting in a vasodilatation of the jugular veins   (MGI Ref ID J:96359)
  • persistent truncus arteriosis
    • defective separation of the aorta from the pulmonary trunk, leading to persistent truncus arteriosis   (MGI Ref ID J:96359)
  • vasculature congestion
    • venous congestion   (MGI Ref ID J:96359)
  • ventricular septal defect   (MGI Ref ID J:96359)
  • endocrine/exocrine gland phenotype
  • abnormal parathyroid gland morphology   (MGI Ref ID J:96359)
    • absent parathyroid glands
      • 2 of 5 do not have parathyroid glands   (MGI Ref ID J:96359)
    • parathyroid hypoplasia
      • 3 of 5 exhibit hypoplastic parathyroid glands at E18   (MGI Ref ID J:96359)
  • small thymus
    • thymus gland is 58% the size of wild-type at E18   (MGI Ref ID J:96359)
  • immune system phenotype
  • small thymus
    • thymus gland is 58% the size of wild-type at E18   (MGI Ref ID J:96359)
  • nervous system phenotype
  • abnormal hindbrain morphology
    • hindbrain abnormalities   (MGI Ref ID J:96359)
  • abnormal midbrain morphology
    • midbrain abnormalities   (MGI Ref ID J:96359)
  • abnormal neural crest cell morphology
    • defect in neural crest cell differentiation in the pharyngeal apparatus but not in the migration or survival of neural crest cells   (MGI Ref ID J:96359)
    • absence of neural crest-derived smooth muscle cells   (MGI Ref ID J:96359)
  • skeleton phenotype
  • abnormal cartilage morphology
    • malformation of cartilage at E18   (MGI Ref ID J:96359)
  • abnormal craniofacial bone morphology
    • malformations of cranial bones at E18   (MGI Ref ID J:96359)
  • hematopoietic system phenotype
  • small thymus
    • thymus gland is 58% the size of wild-type at E18   (MGI Ref ID J:96359)
  • digestive/alimentary phenotype
  • cleft secondary palate   (MGI Ref ID J:96359)
    • palatal shelves fail to meet at midline   (MGI Ref ID J:96359)
  • embryogenesis phenotype
  • abnormal neural crest cell morphology
    • defect in neural crest cell differentiation in the pharyngeal apparatus but not in the migration or survival of neural crest cells   (MGI Ref ID J:96359)
    • absence of neural crest-derived smooth muscle cells   (MGI Ref ID J:96359)
  • muscle phenotype
  • abnormal vasodilation
    • exhibit vasodilatation of the jugular veins   (MGI Ref ID J:96359)
  • growth/size/body phenotype
  • cleft secondary palate   (MGI Ref ID J:96359)
    • palatal shelves fail to meet at midline   (MGI Ref ID J:96359)

Tg(AMELX-cre)A1Kul/0 Tgfbr2tm1Karl/Tgfbr2tm1Karl

        involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/NCr
  • craniofacial phenotype
  • abnormal enamel morphology
    • mandibular molars show a flattened enamel layer in 3-month old animals   (MGI Ref ID J:205404)
    • reduced enamel thickness
      • enamel is thinner along molar cusps in 3-month old animals   (MGI Ref ID J:205404)
  • abnormal molar morphology
    • x-ray analysis reveals dental attrition of the molar cusps at 3 months   (MGI Ref ID J:205404)
  • abnormal tooth mineralization
    • flattened enamel layer suggests that the molar enamel has a mineralization defect resulting in increased attrition with age   (MGI Ref ID J:205404)
    • a >2-fold decrease in molar-mineralized enamel volume is observed at 1 and 2 months compared to controls   (MGI Ref ID J:205404)
    • hypomineralized enamel can not be clearly separated from bone and dentin   (MGI Ref ID J:205404)
    • molar outer aprismatic enamel shows irregular organization with increased porosity   (MGI Ref ID J:205404)
    • enamel crystallites are thin and prismatic showing disorganization   (MGI Ref ID J:205404)
    • in mutants ameloblast morphology appears normal in teeth   (MGI Ref ID J:205404)
  • growth/size/body phenotype
  • abnormal enamel morphology
    • mandibular molars show a flattened enamel layer in 3-month old animals   (MGI Ref ID J:205404)
    • reduced enamel thickness
      • enamel is thinner along molar cusps in 3-month old animals   (MGI Ref ID J:205404)
  • abnormal molar morphology
    • x-ray analysis reveals dental attrition of the molar cusps at 3 months   (MGI Ref ID J:205404)
  • abnormal tooth mineralization
    • flattened enamel layer suggests that the molar enamel has a mineralization defect resulting in increased attrition with age   (MGI Ref ID J:205404)
    • a >2-fold decrease in molar-mineralized enamel volume is observed at 1 and 2 months compared to controls   (MGI Ref ID J:205404)
    • hypomineralized enamel can not be clearly separated from bone and dentin   (MGI Ref ID J:205404)
    • molar outer aprismatic enamel shows irregular organization with increased porosity   (MGI Ref ID J:205404)
    • enamel crystallites are thin and prismatic showing disorganization   (MGI Ref ID J:205404)
    • in mutants ameloblast morphology appears normal in teeth   (MGI Ref ID J:205404)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Hematological Research
Hematopoietic Defects
Immunological Defects

Immunology, Inflammation and Autoimmunity Research
Immunodeficiency
Inflammation

Internal/Organ Research
Wound Healing
      delayed/impaired

Research Tools
Cre-lox System
      loxP-flanked Sequences

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tgfbr2tm1Karl
Allele Name targeted mutation 1, Stefan Karlsson
Allele Type Targeted (Conditional ready (e.g. floxed), No functional change)
Common Name(s) T-Beta-RII flox; Tgfbr2fl; Tgfbr2fl; floxed-TbetaRII;
Mutation Made By Stefan Karlsson,   Lund University Hospital
Strain of Origin(129X1/SvJ x 129S1/Sv)F1-Kitl<+>
Gene Symbol and Name Tgfbr2, transforming growth factor, beta receptor II
Chromosome 9
Gene Common Name(s) 1110020H15Rik; AAT3; AU042018; FAA3; LDS1B; LDS2; LDS2B; MFS2; RIIC; RIKEN cDNA 1110020H15 gene; TAAD2; TBR-II; TGF-beta 2; TGFR-2; TGFbeta-RII; TbetaR-II; TbetaRII; Tgfbr2T; expressed sequence AU042018;
Molecular Note Exon 4 was left flanked by single loxP sites in introns 3 and 5 after a floxed neo cassette was excised via cre-mediated recombination in ES cells. [MGI Ref ID J:77844]

Genotyping

Genotyping Information

Genotyping Protocols

Tgfbr2tm1Karl, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Leveen P; Larsson J; Ehinger M; Cilio CM; Sundler M; Sjostrand LJ; Holmdahl R; Karlsson S. 2002. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100(2):560-8. [PubMed: 12091349]  [MGI Ref ID J:77844]

Additional References

Tgfbr2tm1Karl related

Allinson KR; Lee HS; Fruttiger M; McCarty J; Arthur HM. 2012. Endothelial expression of TGFbeta type II receptor is required to maintain vascular integrity during postnatal development of the central nervous system. PLoS One 7(6):e39336. [PubMed: 22745736]  [MGI Ref ID J:187936]

Arnold TD; Ferrero GM; Qiu H; Phan IT; Akhurst RJ; Huang EJ; Reichardt LF. 2012. Defective Retinal Vascular Endothelial Cell Development As a Consequence of Impaired Integrin alphaVbeta8-Mediated Activation of Transforming Growth Factor-beta. J Neurosci 32(4):1197-206. [PubMed: 22279205]  [MGI Ref ID J:180505]

Buchmann-Moller S; Miescher I; John N; Krishnan J; Deng CX; Sommer L. 2009. Multiple lineage-specific roles of Smad4 during neural crest development. Dev Biol 330(2):329-38. [PubMed: 19361496]  [MGI Ref ID J:149223]

Carvalho RL; Itoh F; Goumans MJ; Lebrin F; Kato M; Takahashi S; Ema M; Itoh S; van Rooijen M; Bertolino P; Ten Dijke P; Mummery CL. 2007. Compensatory signalling induced in the yolk sac vasculature by deletion of TGF receptors in mice. J Cell Sci 120(Pt 24):4269-77. [PubMed: 18029401]  [MGI Ref ID J:128498]

Carvalho RL; Jonker L; Goumans MJ; Larsson J; Bouwman P; Karlsson S; Dijke PT; Arthur HM; Mummery CL. 2004. Defective paracrine signalling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 131(24):6237-47. [PubMed: 15548578]  [MGI Ref ID J:98373]

Cho A; Haruyama N; Hall B; Danton MJ; Zhang L; Arany P; Mooney DJ; Harichane Y; Goldberg M; Gibson CW; Kulkarni AB. 2013. TGF-ss regulates enamel mineralization and maturation through KLK4 expression. PLoS One 8(11):e82267. [PubMed: 24278477]  [MGI Ref ID J:205404]

Chou CK; Schietinger A; Liggitt HD; Tan X; Funk S; Freeman GJ; Ratliff TL; Greenberg NM; Greenberg PD. 2012. Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol 189(8):3936-46. [PubMed: 22984076]  [MGI Ref ID J:190653]

Colak D; Mori T; Brill MS; Pfeifer A; Falk S; Deng C; Monteiro R; Mummery C; Sommer L; Gotz M. 2008. Adult neurogenesis requires Smad4-mediated bone morphogenic protein signaling in stem cells. J Neurosci 28(2):434-46. [PubMed: 18184786]  [MGI Ref ID J:131092]

Delgoffe GM; Woo SR; Turnis ME; Gravano DM; Guy C; Overacre AE; Bettini ML; Vogel P; Finkelstein D; Bonnevier J; Workman CJ; Vignali DA. 2013. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501(7466):252-6. [PubMed: 23913274]  [MGI Ref ID J:201899]

Denton CP; Khan K; Hoyles RK; Shiwen X; Leoni P; Chen Y; Eastwood M; Abraham DJ. 2009. Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol 129(1):194-204. [PubMed: 18563179]  [MGI Ref ID J:146700]

Doisne JM; Bartholin L; Yan KP; Garcia CN; Duarte N; Le Luduec JB; Vincent D; Cyprian F; Horvat B; Martel S; Rimokh R; Losson R; Benlagha K; Marie JC. 2009. iNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med 206(6):1365-78. [PubMed: 19451264]  [MGI Ref ID J:149449]

El-Gohary Y; Tulachan S; Wiersch J; Guo P; Welsh C; Prasadan K; Paredes J; Shiota C; Xiao X; Wada Y; Diaz M; Gittes G. 2014. A smad signaling network regulates islet cell proliferation. Diabetes 63(1):224-36. [PubMed: 24089514]  [MGI Ref ID J:209044]

Falk S; Wurdak H; Ittner LM; Ille F; Sumara G; Schmid MT; Draganova K; Lang KS; Paratore C; Leveen P; Suter U; Karlsson S; Born W; Ricci R; Gotz M; Sommer L. 2008. Brain area-specific effect of TGF-beta signaling on Wnt-dependent neural stem cell expansion. Cell Stem Cell 2(5):472-83. [PubMed: 18462697]  [MGI Ref ID J:149800]

Fan Q; Gu D; Liu H; Yang L; Zhang X; Yoder MC; Kaplan MH; Xie J. 2014. Defective TGF-beta signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. Cancer Res 74(2):471-83. [PubMed: 24282281]  [MGI Ref ID J:206729]

Frutkin AD; Shi H; Otsuka G; Leveen P; Karlsson S; Dichek DA. 2006. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J Mol Cell Cardiol 41(4):724-31. [PubMed: 16887142]  [MGI Ref ID J:114624]

Guasch G; Schober M; Pasolli HA; Conn EB; Polak L; Fuchs E. 2007. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12(4):313-27. [PubMed: 17936557]  [MGI Ref ID J:125988]

Havenar-Daughton C; Li S; Benlagha K; Marie JC. 2012. Development and function of murine RORgammat(+) iNKT cells are under TGF-beta signaling control. Blood 119(15):3486-94. [PubMed: 22371886]  [MGI Ref ID J:183768]

Jaffe M; Sesti C; Washington IM; Du L; Dronadula N; Chin MT; Stolz DB; Davis EC; Dichek DA. 2012. Transforming Growth Factor-beta Signaling in Myogenic Cells Regulates Vascular Morphogenesis, Differentiation, and Matrix Synthesis. Arterioscler Thromb Vasc Biol 32(1):e1-e11. [PubMed: 21979435]  [MGI Ref ID J:179089]

James JM; Nalbandian A; Mukouyama YS. 2013. TGFbeta signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin. Development 140(18):3903-14. [PubMed: 23946447]  [MGI Ref ID J:204444]

Leveen P; Carlsen M; Makowska A; Oddsson S; Larsson J; Goumans MJ; Cilio CM; Karlsson S. 2005. TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo. Blood 106(13):4234-40. [PubMed: 16131565]  [MGI Ref ID J:124057]

Marie JC; Liggitt D; Rudensky AY. 2006. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25(3):441-54. [PubMed: 16973387]  [MGI Ref ID J:113553]

Meng XM; Huang XR; Xiao J; Chen HY; Zhong X; Chung AC; Lan HY. 2012. Diverse roles of TGF-beta receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol 227(2):175-88. [PubMed: 22190171]  [MGI Ref ID J:183441]

Oe S; Lemmer ER; Conner EA; Factor VM; Leveen P; Larsson J; Karlsson S; Thorgeirsson SS. 2004. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 40(5):1098-105. [PubMed: 15389868]  [MGI Ref ID J:105591]

Oshimori N; Fuchs E. 2012. Paracrine TGF-beta signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell 10(1):63-75. [PubMed: 22226356]  [MGI Ref ID J:181500]

Robson A; Allinson KR; Anderson RH; Henderson DJ; Arthur HM. 2010. The TGFbeta type II receptor plays a critical role in the endothelial cells during cardiac development. Dev Dyn 239(9):2435-2442. [PubMed: 20652948]  [MGI Ref ID J:163274]

Schober M; Fuchs E. 2011. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-{beta} and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A 108(26):10544-9. [PubMed: 21670270]  [MGI Ref ID J:173553]

Schramek D; Sendoel A; Segal JP; Beronja S; Heller E; Oristian D; Reva B; Fuchs E. 2014. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343(6168):309-13. [PubMed: 24436421]  [MGI Ref ID J:207490]

Sledzinska A; Hemmers S; Mair F; Gorka O; Ruland J; Fairbairn L; Nissler A; Muller W; Waisman A; Becher B; Buch T. 2013. TGF-beta signalling is required for CD4(+) T cell homeostasis but dispensable for regulatory T cell function. PLoS Biol 11(10):e1001674. [PubMed: 24115907]  [MGI Ref ID J:204579]

Wurdak H; Ittner LM; Lang KS; Leveen P; Suter U; Fischer JA; Karlsson S; Born W; Sommer L. 2005. Inactivation of TGFbeta signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes Dev 19(5):530-5. [PubMed: 15741317]  [MGI Ref ID J:96359]

Xiao X; Wiersch J; El-Gohary Y; Guo P; Prasadan K; Paredes J; Welsh C; Shiota C; Gittes GK. 2013. TGFbeta receptor signaling is essential for inflammation-induced but not beta-cell workload-induced beta-cell proliferation. Diabetes 62(4):1217-26. [PubMed: 23248173]  [MGI Ref ID J:208589]

Yamazaki S; Ema H; Karlsson G; Yamaguchi T; Miyoshi H; Shioda S; Taketo MM; Karlsson S; Iwama A; Nakauchi H. 2011. Nonmyelinating schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147(5):1146-58. [PubMed: 22118468]  [MGI Ref ID J:178929]

Zhang N; Bevan MJ. 2012. TGF-beta signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol 13(7):667-73. [PubMed: 22634866]  [MGI Ref ID J:187653]

Zhang N; Bevan MJ. 2013. Transforming growth factor-beta signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. Immunity 39(4):687-96. [PubMed: 24076049]  [MGI Ref ID J:208203]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony mice homozygous for the floxed allele may be bred together.
Mating SystemHomozygote x Homozygote         (Female x Male)   25-NOV-13
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $239.00Female or MaleHomozygous for Tgfbr2tm1Karl  
Price per Pair (US dollars $)Pair Genotype
$478.00Homozygous for Tgfbr2tm1Karl x Homozygous for Tgfbr2tm1Karl  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $310.70Female or MaleHomozygous for Tgfbr2tm1Karl  
Price per Pair (US dollars $)Pair Genotype
$621.40Homozygous for Tgfbr2tm1Karl x Homozygous for Tgfbr2tm1Karl  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)